GlassScriptPhysician profile
Brett Lyndon Smith
NPI 1316265887
$587,067.64
in general payments reported to CMS, 2019-2025
29 companies · $142K in 2025
The $142K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $42K · 2021: $56K · 2022: $101K · 2023: $94K · 2024: $75K · 2025: $142K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $231K · Consulting Fee: $38K · Travel and Lodging: $36K · Food and Beverage: $6,110 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $230,518.00 |
| Consulting Fee | $37,947.00 |
| Travel and Lodging | $35,984.69 |
| Food and Beverage | $6,110.38 |
| Education | $143.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $504,765.13 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $28,598.46 | 2019-2025 | Simponi Aria, Tremfya |
| Ucb, INC. | $13,157.95 | 2019-2023 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $11,967.72 | 2022-2023 | Stelara, Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $8,176.30 | 2019-2025 | Ilaris |
| Genzyme Corporation | $5,710.56 | 2020-2023 | |
| Regeneron Pharmaceuticals, INC. | $5,620.80 | 2019 | |
| Pfizer INC. | $4,061.33 | 2019-2023 | |
| Amgen INC. | $2,221.16 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Global Services, LLC | $1,400.00 | 2021 | |
| Lilly USA, LLC | $304.13 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $179.59 | 2020-2021 | |
| Adc Therapeutics America, INC. | $97.78 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $90.38 | 2021-2023 | Saphnelo |
| Glaxosmithkline, LLC. | $83.91 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $79.31 | 2019-2023 | Krystexxa |
| Regeneron Healthcare Solutions, INC. | $73.81 | 2019 | |
| Radius Health, INC. | $70.61 | 2019-2021 | |
| Genentech USA, INC. | $56.91 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $47.23 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $44.32 | 2021-2022 | |
| Sobi, INC | $44.16 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.06 | 2019-2020 | |
| Celgene Corporation | $34.91 | 2019 | |
| Alexion Pharmaceuticals, INC. | $32.18 | 2020-2024 | Strensiq |
| Ibsa Pharma INC. | $31.32 | 2022-2024 | Licart, Tirosint |
| Mallinckrodt Hospital Products INC. | $31.12 | 2021-2022 | |
| Grt US Holding, INC. | $26.57 | 2022 | |
| Kyowa Kirin, INC. | $15.93 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.